
==== Front
Eur J Pediatr
Eur J Pediatr
European Journal of Pediatrics
0340-6199
1432-1076
Springer Berlin Heidelberg Berlin/Heidelberg

39120698
5709
10.1007/s00431-024-05709-x
Research
Lowering platelet-count threshold for transfusion in preterm neonates decreases the number of transfusions without increasing severe hemorrhage events
http://orcid.org/0000-0001-9217-0717
Billion Elodie elodie.billion@chu-lyon.fr

14
Ghattas Souad 1
Jarreau Pierre-Henri 13
Irmesi Roberta 1
Ndoudi Likoho Bellaure 1
Patkai Juliana 1
Zana-Taieb Elodie 12
Torchin Heloise 13
1 grid.508487.6 0000 0004 7885 7602 Department of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre, Université Paris Cité, 75014 Paris, France
2 https://ror.org/05f82e368 grid.508487.6 0000 0004 7885 7602 Université Paris Cité, Inserm U955, Paris, France
3 grid.508487.6 0000 0004 7885 7602 CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, INSERM, INRAE, Université Paris Cité, 75004 Paris, France
4 https://ror.org/006yspz11 grid.414103.3 0000 0004 1798 2194 Réanimation Néonatale, Hôpital Femme Mère Enfant, 59 Bd Pinel, 69500 Bron, France
Communicated by Daniele De Luca

9 8 2024
9 8 2024
2024
183 10 44174424
5 6 2024
29 7 2024
31 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Thrombocytopenia is common in preterm neonates and can be associated with hemorrhage. Most platelet transfusions are prophylactic. Previously, higher platelet-count thresholds were recommended for neonates, but this recommendation has been questioned in recent studies. In the PlaNeT2 trial, mortality and serious bleeding were more frequent in neonates with the highest platelet-count threshold than in others. Following this trial, we changed our platelet transfusion practice by lowering the platelet-count threshold for prophylactic transfusion from 50,000 to 25,000/mm3. We conducted a before–after retrospective cohort study to quantify the frequency of platelet transfusions and assess the new protocol by analyzing death and serious hemorrhage events. This retrospective monocentric study included neonates born before 37 weeks of gestation with platelet count < 150,000/mm3 during the 2 years preceding the new platelet transfusion protocol (high prophylactic transfusion threshold, 50,000/mm3) and during the 2 years after the new platelet transfusion protocol (low prophylactic transfusion threshold, 25,000/mm3). The primary outcome was the proportion of neonates receiving at least one platelet transfusion in both groups. We also compared the proportion of deaths and severe hemorrhage events. A total of 707 neonates with thrombocytopenia were identified. In the high-threshold group, 99/360 (27.5%) received at least one platelet transfusion as compared with 56/347 (16.1%) in the low-threshold group (p < 0.001). The groups did not differ in proportion of deaths or severe hemorrhage events.

Conclusions: A reduced platelet-count threshold for transfusion allowed for a significant reduction in the number of platelet transfusions without increasing severe hemorrhage events. What is Known:

• A recent randomized trial suggested that restrictive platelet-count thresholds for platelet transfusion could be beneficial for preterm neonates.

	
What is New:

• On lowering the platelet-count threshold for transfusion from 50,000 to 25,000/mm3, the number of transfusions significantly decreased without increasing severe hemorrhage events in a neonatal intensive care unit.

	

Supplementary Information

The online version contains supplementary material available at 10.1007/s00431-024-05709-x.

Keywords

Neonates
Preterm
Platelet transfusion
Threshold
Hemorrhage
Hospices Civils de LyonOpen access funding provided by Hospices Civils de Lyon.

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

The management of thrombocytopenia (platelet count < 150,000/mm3) in neonatal intensive care units (NICUs) involves platelet transfusion and aims at preventing hemorrhage, specifically in very preterm neonates who are at risk of high-grade intraventricular and intra-parenchymal hemorrhage [1–3]. Nearly 10% of the neonates admitted to NICUs receive a platelet transfusion [4, 5]. However, evidence guiding platelet transfusion practices in preterm neonates is sparse and is mainly based on expert opinion. Hence, the platelet-count threshold for transfusion varies considerably among countries, from 20,000 to 100,000/mm3 [6–8]. In France, recommendations were updated in 2015 and advocated a threshold of < 30,000/mm3 for neonates with non-immune thrombocytopenia and 50,000/mm3 for neonates with risk factors [9].

Overall, 90 to 98% of platelet transfusions in NICUs are prophylactic (i.e., prior to any hemorrhage) [10]. However, there is insufficient evidence to show a causal association between platelet count and risk of hemorrhage. Recent studies support lowering the platelet-count threshold for transfusion without increasing the risk of hemorrhage [10–12]. Among these studies, the PlaNeT2 randomized trial compared platelet transfusion thresholds of 25,000 and 50,000/mm3 in preterm neonates. Mortality, serious hemorrhage events, and significant neurodevelopmental impairment at 2 years of corrected age were more frequent in neonates with the highest threshold than others [13–15]. Potential complications of platelet transfusion should also be considered [6, 14, 15]. Multiple studies have shown an association between platelet transfusions and neonatal mortality [16–20].

The platelet-count threshold for transfusion was modified in our NICU after the publication of the PlaNeT2 results [13], from a prophylactic platelet-count threshold of 50,000 to one of 25,000/mm3 in most cases. We conducted a before–after retrospective cohort study to quantify the frequency of platelet transfusions and assess the new protocol’s tolerance by analyzing death and serious hemorrhage events.

Methods

Setting

Our department is a NICU within a type 3 maternity hospital with 5500 births per year. About 1250 neonates per year are admitted to the NICU. All neonates delivered before 34 weeks of gestation (WG) undergo neurosensory investigations, in particular cerebral ultrasonography twice in the first 10 days and at 3 weeks of life. Ultrasonography is performed more often in cases of clinical instability.

Platelet-count thresholds for transfusion and protocols

The results of PlaNeT2 were presented in a weekly literature review. After that, we updated the platelet transfusion protocol after a discussion with the medical team. Until December 2020, the prophylactic platelet-count threshold for transfusion was 50,000/mm3. In cases of surgery or active hemorrhage, the threshold was set at 80,000 to 100,000/mm3.

Since December 2020, our local protocol has recommended a platelet-count threshold for transfusion of 25,000/mm3. In cases of active hemorrhage or serious hemorrhage in the previous 72 h, lumbar puncture, hemodynamic instability, or gestational age < 26 WG in the first 72 h of life, the threshold is 50,000/mm3. Serious hemorrhage was defined as high-grade intraventricular hemorrhage or pulmonary or digestive hemorrhage.

Transfusion modalities are in line with the 2015 French recommendations, that is, apheresis platelet concentrates from a single donor with pediatric processing, deplasmatized in case of alloimmune thrombocytopenia, and treated with amotosalen, respecting the ABO system whenever possible. The volume transfused is 15 to 20 ml/kg or 0.1 to 0.2 × 1011 platelets/kg over 60 min. The transfusion is administered by a peripheral venous catheter or the second line of an umbilical venous catheter.

Study design and population

In this retrospective monocentric study, we included all neonates born at < 37 WG and admitted to the NICU from 1 January 2018 to 31 December 2019 (representing the high-threshold (HT) group) and from 1 January 2021 to 31 December 2022 (representing the low-threshold (LT) group). Neonates were eligible for the study if they presented at least one episode of thrombocytopenia (platelet count < 150,000/mm3) during their neonatal stay. Exclusion criteria were false severe thrombocytopenia defined as platelet count < 50,000/mm3 and controlled at > 150,000/mm3 in the following 12 h without any transfusion.

Outcomes

The primary outcome was the number of neonates receiving at least one platelet transfusion. Secondary outcomes were the number of transfusions per neonate who received a platelet transfusion and rates of death and severe hemorrhage events within 28 days after a diagnosis of severe thrombocytopenia < 50,000/mm3. Severe hemorrhage was defined as rectal hemorrhage, grade 3 or 4 intraventricular hemorrhage according to Papile’s classification (23), pulmonary hemorrhage (fresh bleeding through an endotracheal tube with increased ventilatory requirements), or hemorrhage associated with shock.

Data collection

The study was declared to the institution’s registry (no. 20220701152308). Parents were informed that their newborn’s data could be used to evaluate medical practices and that they had the right to object. Data were obtained retrospectively from health records and included data on the antenatal period and thrombocytopenia and platelet transfusion. The main neonatal characteristics and outcomes were also recorded. For neonates with severe thrombocytopenia (< 50,000/mm3), additional data collected were red blood cell transfusion, complications occurring in the 28 days after the diagnosis of severe thrombocytopenia (digestive hemorrhage, high-grade intraventricular hemorrhage, death) and occurrence of bronchopulmonary dysplasia.

Statistical analysis

Descriptive statistics were used to summarize the data. Categorical variables are described with number (percentage) and were compared by chi-squared test. Quantitative data are described with mean (SD) and were compared by the Student t-test. We compared the perinatal characteristics of infants and biological results concerning platelet counts in both periods, the 2 years preceding the new platelet transfusion protocol (HT threshold) and the 2 years after the new platelet transfusion protocol (LT threshold). We also compared characteristics of neonates receiving at least one platelet transfusion in both periods. We describe the outcomes of infants with severe thrombocytopenia. We compared the characteristics of infants with severe (< 50,000/mm3) and moderate (50–150,000/mm3) thrombocytopenia. All analyses involved using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) with significance set at p < 0.05.

Results

We identified 707 patients with thrombocytopenia: 360 in the HT group and 347 in the LT group. Baseline characteristics are presented in Table 1. The groups were comparable in characteristics, except for fewer cesarean deliveries and fewer neonates with intra-uterine growth restriction in the HT than in the LT group. Table 1 Characteristics of neonates with high and low platelet-count thresholds

	High threshold (50,000/mm3)
n = 360	Low threshold (25,000/mm3)
n = 347	p-value	
General characteristics	
Gestational age (WG) (mean, SD)	29.0 (3.8)	29.4 (3.8)	0.21	
Gestational age (range)	23–36	23–36		
Gestational age (WG) (n/N, %)	
 < 26	113/360 (31.4)	79/347 (22.8)	0.09	
26–28	63/360 (17.5)	70/347 (20.2)	
28–32	89/360 (24.7)	93/347 (26.8)	
 ≥ 32	95/360 (26.4)	105/347 (30.3)	
Birthweight (g) (mean, SD)	1121 (577)	1166 (577)	0.30	
Birthweight (g) (range)	415–3710	460–3225		
Birthweight (g) (n/N, %)	
 < 800	149/358 (41.6)	118/347 (31)	0.16	
800–1200	87/358 (24.3)	102/347 (29.5)	
1200–1600	53/358 (14.8)	49/347 (14.2)	
 ≥ 1600	95/358 (26.4)	77/347 (22.3)	
Intrauterine growth restriction (n/N, %)	157/358 (43.9)	191/347 (55.0)	 < 0.01	
Male sex (n/N, %)	198/359 (55.2)	177/347 (51.0)	0.27	
Antenatal characteristics (n/N, %)	
Multiple pregnancy	82/358 (22.9)	87/346 (25.1)	0.49	
Outborn	37/359 (10.3)	48/347 (13.8)	0.15	
Cesarean delivery	210/359 (58.5)	230/347 (66.3)	0.03	
Antenatal glucocorticoids, ≥ 1 dose	293/342 (85.7)	270/304 (88.8)	0.23	
Preeclampsia	98/359 (27.3)	111/347 (32.0)	0.17	
Chorioamnionitis	91/359 (25.3)	80/347 (23.1)	0.48	
Denominators vary due to missing data

WG weeks of gestation

The LT and HT groups had similar mean platelet counts at birth and evolution during the first postnatal days (Table 2). In the HT group, 99/360 (27.5%) patients received at least one platelet transfusion as compared with 56/347 (16.1%) in the LT group (p < 0.001), for a relative risk reduction of 41%. The mean number of platelet transfusions per patient was 1.8 (SD 1.6) in the LT group and 2.4 (SD 2.4) in the HT group (p < 0.01). This reduction was accompanied by a reduction in volume transfused: mean 27.5 (SD 24.7) ml/kg in the LT group and 35.0 (SD 35.3) ml/kg in the HT group. Additional investigations were conducted for about 40% of the neonates in cases of persistent thrombocytopenia that was not explained by growth retardation or sepsis. The most frequently investigated condition was cytomegalovirus infection, investigated in nearly 40% of all neonates included but positive for only 3.1%. Table 2 Characteristics of thrombocytopenia for neonates with high and low platelet-count thresholds

	High threshold (50,000/mm3)
n = 360	Low threshold (25,000/mm3)
n = 347	p-value	
Platelet count at birth, /mm3 (mean, SD)	179,000 (76,000)	177,000 (74,000)	0.76	
Platelet count nadir, /mm3 (mean, SD)	83,000 (40,000)	86,000 (42,000)	0.42	
Postnatal age at platelet count nadir, days (mean, SD)	7.0 (10.3)	6.8 (9.9)	0.73	
Early-onset severe thrombocytopenia (< 3 days) (n/N, %)	33/360 (9.2)	20/347 (5.8)	0.09	
Thrombocytopenia ≤ 50,000/mm3 (n/N, %)	98/359 (27.3)	90/347 (25.9)	0.68	
Thrombocytopenia ≤ 25,000/mm3 (n/N, %)	30/359 (8.4)	33/347 (9.5)	0.59	
Platelet transfusion (> 1) (n/N, %)	99/360 (27.5)	56/347 (16.1)	 < 0.001	
Denominators vary due to missing data

Overall, 98 neonates in the HT group and 90 in the LT group presented severe thrombocytopenia (platelet count < 50,000/mm3); for these infants, the mean gestational age was 28.1 (SD 3.3) WG and mean birthweight 957 (SD 489) g. Their characteristics and outcomes, in particular death or digestive or intraventricular hemorrhage, are in Table 3. Fewer infants in the LT than in the HT group had complications in the 28 days after the diagnosis of severe thrombocytopenia (28% vs 42%, p = 0.04). Mortality rates were high in both groups: 33.7% in the HT group and 25.6% in the LT group (p = 0.22) (i.e., 29.8% of neonates with severe thrombocytopenia). In comparison, the mortality rate was 9.3% for neonates with moderate thrombocytopenia (platelet count 50 to 150,000/mm3). No pulmonary hemorrhage event was recorded, and only one neonate from the HT group had a retinal hemorrhage. The occurrence of bronchopulmonary dysplasia, defined as the need for ventilatory support (oxygen or invasive and non-invasive ventilation at 36 WG), was quite high, at 63% among neonates with thrombocytopenia < 50 G/l and comparable in the two groups. However, Table 3 presents data on neonates who had severe thrombocytopenia < 50,000 platelets/mm3, which is a marker of overall severity. Among thrombocytopenic children with > 50,000 platelets/mm3, the occurrence of bronchopulmonary dysplasia is lower (161/351 or 45.9%). Table 3 Outcomes of neonates with severe thrombocytopenia < 50,000/mm3 and high and low platelet-count thresholds whether they received transfusion or not

	All	High threshold (50,000/mm3)	Low threshold (25,000/mm3)	p	
N = 188	N = 98	N = 90		
Complications within 28 days after diagnosis of severe thrombocytopenia (n/N, %)	
None	116/179 (64.8)	52/90 (57.8)	64/89 (71.9)	0.04	
Digestive hemorrhage	2/1479 (1.1)	1/90 (1.1)	1/89 (1.1)	0.99	
Grade 3 or 4 intraventricular hemorrhage	4/179 (2.2)	3/90 (3.3)	1/89 (1.1)	0.32	
Death	56/188 (29.8)	33/98 (33.7)	23/90 (25.6)	0.22	
Red blood cell transfusion (n/N, %)	121/177 (68.4)	64/88 (72.7)	57/89 (64.0)	0.21	
Children alive at 36 weeks postmenstrual age	N = 132	N = 65	N = 67		
Bronchopulmonary dysplasia at 36 weeks postmenstrual age* (n/N, %)	66/104 (63.5)	32/54 (59.3)	34/50 (68.0)	0.36	
Denominators vary due to missing data

*Among children alive at 36 weeks

We also compared the baseline characteristics of neonates with severe versus moderate thrombocytopenia (platelet count 50,000 to 150,000/mm3); the results are in Table S1, supplementary data. Neonates with severe thrombocytopenia (platelet count < 50,000/mm3) were more premature and had a lower birthweight than those with moderate thrombocytopenia.

In most cases, the indication for transfusion was asymptomatic thrombocytopenia under the threshold (Table 4). The two groups were similar in clinical condition at first transfusion, with many neonates having sepsis and requiring invasive ventilation (Table 4). Active hemorrhage occurred in 20.2% of the neonates in the HT group and 35.7% in the LT group. Prior hemodynamic instability requiring inotropic support was more frequent but not significantly in the HT than in the LT group. Table 4 Characteristics of neonates at first platelet transfusion according to high or low platelet-count threshold

	High threshold (50,000/mm3)
n = 99	Low threshold (25,000/mm3)
n = 56	p-value	
Gestational age, WG (mean, SD)

N

	27.6 (3.1)

99

	27.9 (3.5)

56

	0.53	
Postnatal age at first transfusion, days (mean, SD)

N

	6.4 (8.5)

99

	8.5 (11.5)

56

	0.20	
Platelet count at first transfusion, /mm3 (mean, SD)

N

	41,000 (15,000)

99

	28,000 (14,000)

56

	 < 0.001	
Postnatal age at last transfusion, days (mean, SD)

N

	11 (12.5)

97

	10 (12)

51

	0.66	
Number of platelet transfusions per patient (mean, SD)

N

	2.4 (2.4)

98

	1.8 (1.6)

55

	 < 0.01	
Volume of transfusion, ml (mean, SD)

Volume of transfusion, ml/kg (mean, SD)

N

	41.5 (57.9)

35.0

99

	28.3 (26.1)

27.5

55

	0.10

0.13

	
Indications for transfusion (n/N, %)	
Asymptomatic thrombocytopenia < threshold	51/99 (51.5)	27/56 (48.2)	0.90	
Sepsis	30/99 (30.3)	9/56 (16.1)	
Active hemorrhage	10/99 (10.1)	15/56 (26.8)	
Non-steroidal anti-inflammatory drug	4/99 (4.0)	0/56 (0)	
Unknown	4/99 (4.0)	5/56 (8.0)	
Transfusion with platelet count greater than current threshold (n/N, %)	14/99 (14.1)	20/56 (35.7)	 < 0.01	
Clinical condition at first transfusion (n/N, %)	
Invasive ventilation	59/99 (59.6)	32/55 (57.1)	0.86	
Sepsis	54/99 (54.5)	34/56 (60.7)	0.46	
Necrotizing enterocolitis	3/98 (3.1)	7/56 (12.5)	0.02	
Active hemorrhage	20/99 (20.2)	20/56 (35.7)	0.03	
Indication for lumbar puncture	12/98 (12.2)	9/56 (16.1)	0.51	
Indication for non-steroidal anti-inflammatory drug	11/98 (11.2)	2/56 (3.6)	0.10	
Grade 3 or 4 intraventricular hemorrhage	15/98 (15.3)	11/56 (19.6)	0.49	
Disseminated intravascular coagulation	6/99 (6.1)	3/56 (5.4)	0.86	
Hemodynamic instability	42/95 (44.2)	16/56 (28.6)	0.06	
Denominators vary due to missing data

IQR interquartile range, WG weeks of gestation

Some neonates (14.4% in the HT group and 20.6% in the LT group) did not meet the platelet-count threshold for transfusion. The mean minimum platelet count was 58,000 (SD 10,000) per cubic millimeter in the HT group and 33,000 (SD 8000) per cubic millimeter in the LT group. Moreover, 12 (3%) neonates in the HT group did not receive a transfusion even though their minimum platelet count was < 50,000/mm3. Seven (60%) had a platelet count very close to the threshold, and the platelet count was above the threshold when it was checked a second time. Two neonates had severe neurological damage, and withholding or withdrawing life-sustaining therapies had been decided. Medical records were incomplete for three neonates of the HT group, and we could not record any information about transfusion. In the LT group, one neonate had a minimum platelet count < 25,000/mm3 and did not receive transfusion. The minimum platelet count occurred in a sepsis context and was close to the threshold (24,000/mm3), with a count of 60,000/mm3 12 h later.

Discussion

In this monocentric retrospective cohort study, a lower platelet-count threshold for transfusion in preterm neonates allowed for a significant reduction in the number of transfusions without increasing severe hemorrhage events. Rates of platelet transfusions in preterm neonates with thrombocytopenia < 150,000/mm3 decreased from 27% in the HT group to 16% in the LT group (i.e., a relative risk reduction of 41%). In both periods, the 2 years preceding the new platelet transfusion protocol (HT threshold) and the 2 years after the new platelet transfusion protocol (LT threshold), severe thrombocytopenia < 50,000/mm3 was associated with high mortality.

However, the change in platelet-count threshold for transfusion was not associated with increased rates of death or severe hemorrhage. This finding in our real-world study agrees with the PlaNeT2 trial results. In this trial, which included infants with platelet count < 100,000/mm3, 90% of the neonates in the HT group and 53% in the LT group received at least one platelet transfusion (i.e., a relative risk reduction of 41% as well). Moreover, morbi-mortality was less frequent in the LT than in the HT group [13]. A recent study, also inspired by the PlaNeT2 trial, did not find a reduction in the number of platelet transfusions after a change in platelet transfusion guidelines [22]. However, the study maintained a threshold of 50,000/mm3 for neonates at risk of intra-ventricular hemorrhage, which concerns many neonates in a NICU. In contrast, in another study, restrictive local transfusion thresholds in a NICU decreased the proportion of platelet-transfused neonates by 46% [23].

Although the protocol with a lower threshold was generally well applied, 36% of the transfusions were performed out of protocol, more in the LT than in the HT group. The new protocol was implemented in December 2020, and our study began in January 2021 so that medical staff could get used to it. To raise awareness among the medical team about the change in the platelet transfusion protocol, we requested that each indication for platelet transfusion be documented in the patient’s record. This gave us the opportunity to reiterate the importance of restrictive transfusion practices. However, staff may have been concerned that the platelet count would quickly fall below the threshold, or they may have wished to avoid repeated blood samples, therefore performing more transfusions. This observation is consistent with the previous study of transfusions [23], finding an adherence to the new protocol of about 70%. To reduce non-indicated transfusions, the Boston Children’s Hospital NICU set up a key driver diagram to improve the staff’s educational effort and encourage staff buy-in [24]. This program included strengthening the education of providers and nursing staff about the need to use restrictive platelet transfusion thresholds, reminding them daily of the protocol change and discussing situations that required clarification. In our case, reviewing evidence about the potential harm of the use of the liberal transfusion threshold and the poor evidence of an association between low platelet count and intra-ventricular hemorrhage would improve adherence to the new protocol.

Recent studies question the association between thrombocytopenia and hemorrhage in neonates, pointing to the limited effectiveness of platelet transfusions in reducing the risk of hemorrhage and even suggesting that platelet transfusions may be harmful [14, 16–21, 26]. One hypothesis is the potential induction of an inflammatory process when neonates are transfused with adult platelets [25]. Platelets may also promote excessive angiogenic signals during a vulnerable period of brain development [27]. Transfusion-related harm may involve hemodynamic parameters, and fast volume expansion after platelet transfusion administration may disrupt blood flow in the brain and increase the risk of hemorrhage [28]. As a result, platelet count may not be the only factor to consider when prescribing transfusion, and some authors suggest that platelet mass and time of occlusion may better predict the risk of hemorrhage [29, 30].

Our study has some limitations. First, it was a single-center retrospective study, which limits the generalization of our results. We also had missing data, for example, the rate of missing data for bronchopulmonary dysplasia is significant (24.5% in the overall population, 21.2% in the population with thrombocytopenia < 50,000/mm3) due to transfers before 36 WG to other hospitals. In these cases, the precise respiratory status at 36 WG was not available. Additionally, the occurrence of bronchopulmonary dysplasia is likely overestimated because transferred neonates generally have a more favorable respiratory outcome than non-transferred neonates. We did not record other aspects of clinical practice that could have changed between the two periods. However, if changes of clinical practice occurred, they probably had a low impact on the risk of thrombocytopenia or major bleeding. Although our study is one of the largest real-world studies of neonates with thrombocytopenia, our sample size might still be too small to draw conclusions about rare side effects.

Our study highlights that lowering the platelet-count threshold for transfusion may result in transfusion savings without increasing complications. This is also the conclusion of a recent meta-analysis of platelet transfusion that recommended the use of restrictive platelet-count thresholds for transfusion in neonates [28]. Platelet transfusion modalities such as volume and duration are still being actively studied and may evolve in the coming years [31].

Conclusion

The findings of this retrospective study suggest that lowering the platelet-count threshold for transfusion in neonates born < 37 WG is associated with fewer transfusions and seems safe. These real-life results are in line with the current trend to reduce the number of platelet transfusions.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 25 KB)

Abbreviations

CMV Cytomegalovirus

IQR Interquartile range

HT High threshold

LT Low threshold

NICU Neonatal intensive care unit

PCR Polymerase chain reaction

WG Weeks of gestation

Acknowledgements

The authors thank Laura Smales for correcting the English.

Authors’ contributions

E.Z.T., H.T., S.G. and E.B. designed the study; S.G. and E.B prepared the data for analysis; H.T. analyzed the data; E.Z.T., H.T., and E.B. interpreted the data; E.B., E.Z.T. and H.T. wrote the report, all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by Hospices Civils de Lyon.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

This is a single-center retrospective observational study. In accordance with the Declaration of Helsinki, the study was declared to APHP as required by RGPD rules (registration number 20220701152308). Parents were informed that their newborn’s data could be used to evaluate medical practices unless they stated their opposition.

Conflict of interest

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Chevallier M Debillon T Pierrat V Delorme P Kayem G Durox M Leading causes of preterm delivery as risk factors for intraventricular hemorrhage in very preterm infants: results of the EPIPAGE 2 cohort study Am J Obstet Gynecol 2017 216 518.e1 518.e12 10.1016/j.ajog.2017.01.002 28104401
Chevallier M, Debillon T, Pierrat V, Delorme P, Kayem G, Durox M et al (2017) Leading causes of preterm delivery as risk factors for intraventricular hemorrhage in very preterm infants: results of the EPIPAGE 2 cohort study. Am J Obstet Gynecol 216:518.e1-518.e1228104401
2. Lai GY Shlobin N Garcia RM Global incidence proportion of intraventricular haemorrhage of prematurity: a meta-analysis of studies published 2010–2020 Arch Dis Child Fetal Neonatal Ed 2022 107 513 519 10.1136/archdischild-2021-322634 34930831
Lai GY, Shlobin N, Garcia RM et al (2022) Global incidence proportion of intraventricular haemorrhage of prematurity: a meta-analysis of studies published 2010–2020. Arch Dis Child Fetal Neonatal Ed 107:513–51934930831
3. Bolisetty S Dhawan A Abdel-Latif M Bajuk B Stack J Oei JL Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants Pediatrics 2014 133 55 62 10.1542/peds.2013-0372 24379238
Bolisetty S, Dhawan A, Abdel-Latif M, Bajuk B, Stack J, Oei JL et al (2014) Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics 133:55–6224379238
4. Christensen RD Henry E Wiedmeier SE Stoddard RA Sola-Visner MC Lambert DK Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system J Perinatol 2006 26 348 353 10.1038/sj.jp.7211509 16642027
Christensen RD, Henry E, Wiedmeier SE, Stoddard RA, Sola-Visner MC, Lambert DK et al (2006) Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 26:348–35316642027
5. Del Vecchio A Sola MC Theriaque DW Hutson AD Kao KJ Wright D Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions Transfusion 2001 41 803 8 10.1046/j.1537-2995.2001.41060803.x 11399824
Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D et al (2001) Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 41:803–811399824
6. Cremer M Sallmon H Kling PJ Bührer C Dame C Thrombocytopenia and platelet transfusion in the neonate Semin Fetal Neonatal Med 2016 21 10 18 10.1016/j.siny.2015.11.001 26712568
Cremer M, Sallmon H, Kling PJ, Bührer C, Dame C (2016) Thrombocytopenia and platelet transfusion in the neonate. Semin Fetal Neonatal Med 21:10–1826712568
7. Del Vecchio A Evaluation and management of thrombocytopenic neonates in the intensive care unit Early Hum Dev 2014 90 S51 S55 10.1016/S0378-3782(14)50014-X 25220130
Del Vecchio A (2014) Evaluation and management of thrombocytopenic neonates in the intensive care unit. Early Hum Dev 90:S51–S5525220130
8. Gunnink SF Vlug R Fijnvandraat K van der Bom JG Stanworth SJ Lopriore E Neonatal thrombocytopenia: etiology, management and outcome Expert Rev Hematol 2014 7 387 395 10.1586/17474086.2014.902301 24665958
Gunnink SF, Vlug R, Fijnvandraat K, van der Bom JG, Stanworth SJ, Lopriore E (2014) Neonatal thrombocytopenia: etiology, management and outcome. Expert Rev Hematol 7:387–39524665958
9. HAS. Recommandations de bonnes pratiques - Transfusion de plaquettes : produits, indications. French guidelines for platelet transfusions. Available online: https://www.has-sante.fr/upload/docs/application/pdf/2015-11/recommandations_-_transfusion_de_plaquettes.pdf. Accessed 6 Aug 2024
10. Stanworth SJ Clarke P Watts T Ballard S Choo L Morris T Prospective, observational study of outcomes in neonates with severe thrombocytopenia Pediatrics 2009 124 e826 e834 10.1542/peds.2009-0332 19841111
Stanworth SJ, Clarke P, Watts T, Ballard S, Choo L, Morris T et al (2009) Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 124:e826–e83419841111
11. Lopriore E Updates in red blood cell and platelet transfusions in preterm neonates Am J Perinatol 2019 36 S37 40 10.1055/s-0039-1691775 31238357
Lopriore E (2019) Updates in red blood cell and platelet transfusions in preterm neonates. Am J Perinatol 36:S37-4031238357
12. Andrew M Vegh P Caco C Kirpalani H Jefferies A Ohlsson A A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants J Pediatr 1993 123 285 291 10.1016/S0022-3476(05)81705-6 8345429
Andrew M, Vegh P, Caco C, Kirpalani H, Jefferies A, Ohlsson A et al (1993) A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 123:285–2918345429
13. Curley A Stanworth SJ Willoughby K Fustolo-Gunnink SF Venkatesh V Hudson C Randomized trial of platelet-transfusion thresholds in neonates N Engl J Med 2019 380 242 251 10.1056/NEJMoa1807320 30387697
Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C et al (2019) Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med 380:242–25130387697
14. Fustolo-Gunnink SF Fijnvandraat K van Klaveren D Stanworth SJ Curley A Onland W Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death Blood 2019 134 2354 2360 10.1182/blood.2019000899 31697817
Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, Stanworth SJ, Curley A, Onland W et al (2019) Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood 134:2354–236031697817
15. Benjamin RJ Dy B Perez J Eder AF Wagner SJ Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results Vox Sang 2014 106 23 30 10.1111/vox.12065 23815166
Benjamin RJ, Dy B, Perez J, Eder AF, Wagner SJ (2014) Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results. Vox Sang 106:23–3023815166
16. Baer VL Lambert DK Henry E Christensen RD Severe thrombocytopenia in the NICU Pediatrics 2009 124 e1095 1100 10.1542/peds.2009-0582 19917581
Baer VL, Lambert DK, Henry E, Christensen RD (2009) Severe thrombocytopenia in the NICU. Pediatrics 124:e1095-110019917581
17. Baer VL Lambert DK Henry E Snow GL Sola-Visner MC Christensen RD Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system J Perinatol 2007 27 790 796 10.1038/sj.jp.7211833 17855804
Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD (2007) Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. J Perinatol 27:790–79617855804
18. Garcia MG Duenas E Sola MC Hutson AD Theriaque D Christensen RD Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit J Perinatol 2001 21 415 420 10.1038/sj.jp.7210566 11894507
Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, Christensen RD (2001) Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 21:415–42011894507
19. Bolat F Kılıç SÇ Oflaz MB Gülhan E Kaya A Güven AS The prevalence and outcomes of thrombocytopenia in a neonatal intensive care unit: a three-year report Pediatr Hematol Oncol 2012 29 710 720 10.3109/08880018.2012.725454 23013425
Bolat F, Kılıç SÇ, Oflaz MB, Gülhan E, Kaya A, Güven AS et al (2012) The prevalence and outcomes of thrombocytopenia in a neonatal intensive care unit: a three-year report. Pediatr Hematol Oncol 29:710–72023013425
20. Davenport PE Wood TR Heagerty PJ Sola-Visner MC Juul SE Patel RM Platelet transfusion and death or neurodevelopmental impairment in children born extremely preterm JAMA Netw Open 2024 7 e2352394 10.1001/jamanetworkopen.2023.52394 38261320
Davenport PE, Wood TR, Heagerty PJ, Sola-Visner MC, Juul SE, Patel RM (2024) Platelet transfusion and death or neurodevelopmental impairment in children born extremely preterm. JAMA Netw Open 7:e235239438261320
21. Burstein J Papile L Burstein R Intraventricular hemorrhage and hydrocephalus in premature newborns: a prospective study with CT Am J Roentgenol 1979 132 631 635 10.2214/ajr.132.4.631 106697
Burstein J, Papile L, Burstein R (1979) Intraventricular hemorrhage and hydrocephalus in premature newborns: a prospective study with CT. Am J Roentgenol 132:631–635106697
22. Bahr TM Christensen TR Henry E Astin M Ilstrup SJ Ohls RK Platelet transfusions in a multi-neonatal intensive care unit health care organization before and after publication of the PlaNeT-2 clinical trial J Pediatr 2023 257 113388 10.1016/j.jpeds.2023.03.003 36933765
Bahr TM, Christensen TR, Henry E, Astin M, Ilstrup SJ, Ohls RK et al (2023) Platelet transfusions in a multi-neonatal intensive care unit health care organization before and after publication of the PlaNeT-2 clinical trial. J Pediatr 257:11338836933765
23. Zabeida A Chartrand L Lacroix J Villeneuve A Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit Transfusion 2023 63 134 142 10.1111/trf.17184 36369934
Zabeida A, Chartrand L, Lacroix J, Villeneuve A (2023) Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit. Transfusion 63:134–14236369934
24. Davenport PE Chan Yuen J Briere J Implementation of a neonatal platelet transfusion guideline to reduce non-indicated transfusions using a quality improvement framework J Perinatol 2021 41 1487 1494 10.1038/s41372-021-01033-6 33758388
Davenport PE, Chan Yuen J, Briere J et al (2021) Implementation of a neonatal platelet transfusion guideline to reduce non-indicated transfusions using a quality improvement framework. J Perinatol 41:1487–149433758388
25. Nguyen KA Hamzeh-Cognasse H Sebban M Fromont E Chavarin P Absi L A Computerized prediction model of hazardous inflammatory platelet transfusion outcomes PLoS ONE 2014 9 e97082 10.1371/journal.pone.0097082 24830754
Nguyen KA, Hamzeh-Cognasse H, Sebban M, Fromont E, Chavarin P, Absi L et al (2014) A Computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS ONE 9:e9708224830754
26. Ribeiro HS Assunção A Vieira RJ Soares P Guimarães H Flor-de-Lima F Platelet transfusions in preterm infants: current concepts and controversies—a systematic review and meta-analysis Eur J Pediatr 2023 182 3433 3443 10.1007/s00431-023-05031-y 37258776
Ribeiro HS, Assunção A, Vieira RJ, Soares P, Guimarães H, Flor-de-Lima F (2023) Platelet transfusions in preterm infants: current concepts and controversies—a systematic review and meta-analysis. Eur J Pediatr 182:3433–344337258776
27. Ferrer-Marin F Chavda C Lampa M Michelson AD Frelinger AL Sola-Visner M Effects of in vitro adult platelet transfusions on neonatal hemostasis J Thromb Haemost 2011 9 1020 1028 10.1111/j.1538-7836.2011.04233.x 21320282
Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger AL, Sola-Visner M (2011) Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost 9:1020–102821320282
28. van der Staaij H Stanworth SJ Fustolo-Gunnink SF Prophylactic platelet transfusions: why less is more Clin Perinatol 2023 50 775 792 10.1016/j.clp.2023.07.007 37866847
van der Staaij H, Stanworth SJ, Fustolo-Gunnink SF (2023) Prophylactic platelet transfusions: why less is more. Clin Perinatol 50:775–79237866847
29. Gerday E Baer VL Lambert DK Paul DA Sola-Visner MC Pysher TJ Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit Transfusion 2009 49 2034 2039 10.1111/j.1537-2995.2009.02253.x 19555422
Gerday E, Baer VL, Lambert DK, Paul DA, Sola-Visner MC, Pysher TJ et al (2009) Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion 49:2034–203919555422
30. Davenport P Sola-Visner M Platelets in the neonate: not just a small adult Res Pract Thromb Haemost 2022 6 3 e12719 10.1002/rth2.12719 35592812
Davenport P, Sola-Visner M (2022) Platelets in the neonate: not just a small adult. Res Pract Thromb Haemost 6(3):e1271935592812
31. Moore CM Curley AE Neonatal platelet transfusions: starting again Transfus Med Rev 2021 35 29 35 10.1016/j.tmrv.2021.06.003 34312045
Moore CM, Curley AE (2021) Neonatal platelet transfusions: starting again. Transfus Med Rev 35:29–3534312045
